Disease model: Familial adenomatous polyposis

Trends in Molecular Medicine

Volumn 7, Issue 8, 2001, Pages 369-373

  Fodde, Riccardo ^a   Smits, Ron ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMATOUS POLYP; ANIMAL MODEL; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE MODEL; FAMILIAL POLYPOSIS; GENE MUTATION; GENOTYPE; HUMAN; MOUSE; NONHUMAN; PHENOTYPE; POLYPOSIS; REVIEW;

EID: 0034902674     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(01)02050-0     Document Type: Review

References (64)

1. Wnt signaling and cancer
2. Linking colorectal cancer to Wnt signaling
3. Genotype-phenotype correlations at the adenomatous polyposis coli (APC) gene
4. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
5. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
6. Loss of Apc+ in intestinal adenomas from Min mice
7. ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias
8. Studies of neoplasia in the Min mouse
9. Apc1638N: A mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts
10. Tumorigenesis in the multiple intestinal neoplasia mouse: Redundancy of negative regulators and specificity of modifiers
11. Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation
12. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse
13. The secretory phospholipase A2 gene is a candidate for the Mom 1 locus, a major modifier of ApcMin-induced intestinal neoplasia
14. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis
15. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene
16. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis
17. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene
18. Morphological and molecular processes of polyp formation in Apc(delta 716) knockout mice
19. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors
20. Apc1638T: A mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development
21. Loss of Apc and the entire chromosome 18 but absence of mutations at the Ras and Tp53 genes in intestinal tumors from Apc1638N, a mouse model for Apc-driven carcinogenesis
22. Intestinal and extra-intestinal tumor multiplicities in the Apc1638N mouse model after exposure to X-rays
23. The genetic background modifies the spontaneous and X-ray-induced tumor spectrum in the Apc1638N mouse model
24. N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: Age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts
25. Retinal pigment epithelium abnormalities in mice with adenomatous polyposis coli gene disruption
26. E-cadherin and adenomatous polyposis coli mutations are synergistic in intestinal tumor initiation in mice
27. Mutations in the APC tumour suppressor gene cause chromosomal instability
28. A role for the adenomatous polyposis coli protein in chromosome segregation
29. Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522
30. Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice
31. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene
32. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy
33. Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas
34. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
35. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
36. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis
37. Mouse models for hereditary nonpolyposis colorectal cancer
38. Somatic Apc mutations are selected upon their capacity to inactivate the β-catenin downregulating activity
39. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice
40. Mlb1 deficiency enhances several phenotypes of Apc(Min)/+ mice
41. Tumor-associated Apc mutations in Mlh1-/-Apc1638N mice reveal a mutational signature of Mlh1 deficiency
42. -/-;Min mice
43. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
44. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: Kinetics, strain effects and resistance to chemosuppression
45. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
46. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
47. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
48. Genotype-phenotype correlation in murine Apc mutation: Differences in enterocyte migration and response to sulindac
49. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin
50. Aspirin prevents tumors in a murine model of familial adenomatous polyposis
51. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months
52. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice
53. Suppression of intestinal polyp development by low-fat and high-fiber diet in Apc(delta716) knockout mice
54. Effects of docosahexaenoic acid (DHA) on intestinal polyp development in Apc Δ716 knockout mice
55. Effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine on intestinal polyp development in Apc delta 716 knockout mice
56. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile
57. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis
58. Short-term carcinogenicity testing of a potent murine intestinal mutagen, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), in Apc1638N transgenic mice
59. ApcMin: A mouse model for intestinal and mammary tumorigenesis
60. Somatic mutational mechanisms involved in intestinal tumor formation in Min mice
61. A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice
62. Loss of heterozygosity in spontaneous and X-ray-induced intestinal tumors arising in F1 hybrid min mice: Evidence for sequential loss of APC(+) and Dpc4 in tumor development
63. Suppression of intestinal neoplasia by DNA hypomethylation